Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer.

Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer.

Akram T; Maseelall P; Fanning J

American Journal of Obstetrics & Gynecology

2005

2005-05

OBJECTIVE: The purpose of this study was to determine the activity and toxicity of carboplatin and paclitaxel (taxol) in the treatment of advanced or recurrent endometrial cancer. STUDY DESIGN: This was a retrospective review of 18 consecutive patients with advanced (stage 4) or recurrent endometrial adenocarcinoma that had been treated with outpatient carboplatin and taxol. Taxol was delivered at 135 mg/m 2 over 3 hours, and carboplatin was delivery at an area under the curve of 5 over 1 hour. Cycles were repeated every 21 days. RESULTS: The overall response rate was 63% with 28% of patients who had a partial response and 35% of patients who had a complete response. Kaplan-Meier test was used to estimate the median survival time of 27 months and the median progression free survival time of 24 months. No patient had neutropenia, thrombocytopenia or grade 3 vomiting, neurosensory toxicity, or renal toxicity. CONCLUSION: Carboplatin and taxol for the treatment of advanced or recurrent endometrial cancer appear to be active regimens with minimal toxicity.

Adult; Aged; Survival; Drug Administration Schedule; Human; Middle Age; Retrospective Design; Neoplasm Recurrence; Antineoplastic Agents; Combined; Kaplan-Meier Estimator; Drug Toxicity; Severity of Illness; Carboplatin – Administration and Dosage; Endometrial Neoplasms – Drug Therapy; Local – Drug Therapy; Paclitaxel – Administration and Dosage

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

1365–1367

5

192